SCHEMBL2120602

SCHEMBL2120602

Cc1ccc(-c2cncc(C#N)c2)cc1NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.45
ACLY P53396 1/20 0.45
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
SLC22A12 Q96S37 2/20 0.42
PIK3CD O00329 1/20 0.42
NR3C2 P08235 1/20 0.42
PIK3CB P42338 2/20 0.42
GRIA2 P42262 1/20 0.41
PIK3CG P48736 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAP4K4 O95819 1/20 0.41
PI4KA P42356 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120558 0.89 ACLY (0.45) HSD11B1ACLYPIK3CAMTORSLC22A12
SCHEMBL2118452 0.89 TP53 (0.48) HSD11B1ACLYSLC22A12PIK3CDNR3C2
SCHEMBL2119785 0.86 ACLY (0.59) HSD11B1ACLYPIK3CAMTOR
SCHEMBL2119726 0.82 KDM1A (0.48) HSD11B1ACLYPIK3CAMTORSLC22A12
SCHEMBL2118686 0.81 PIK3CD (0.47) HSD11B1ACLYPIK3CAMTORPIK3CD
SCHEMBL2120193 0.81 ACLY (0.46) HSD11B1ACLYALDH1A1CYP3A4SMN1; SMN2
SCHEMBL2120031 0.81 ACLY (0.44) HSD11B1ACLYALDH1A1CYP3A4SMN1; SMN2
SCHEMBL2118244 0.80 ABCB1 (0.51) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL2118451 0.79 ALDH1A1 (0.48) PIK3CDALDH1A1CYP3A4SMN1; SMN2TDP1
SCHEMBL22230488 0.78 PIK3CG (0.56) ACLYPIK3CAMTORPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 HSD11B1 3280/4885ACLY 1360/4885PIK3CA 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.